Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yangtze River Pharma Signs $338 Million Deal for Gastro Reflux Therapy

publication date: Mar 18, 2021

Yangtze River Pharma signed a $338 million deal for China rights to a gastroesophageal reflux treatment from South Korea's Daewoong Pharma. Fexuprazan is a novel potassium-competitive acid blocker (P-CAB) developed by Daewoong, which blocks the proton pump that secretes gastric acids from the stomach wall. Daewonong successfully completed a Korean Phase III clinical trial for the therapy in 2019. The agreement includes an $18 million upfront payment and $12 million in development milestones. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital